CPP-115
Experimental drug
From Wikipedia, the free encyclopedia
CPP-115 is an experimental drug being studied for the treatment of various neurological and psychiatric disorders including cocaine addiction,[1] infantile spasms,[2][3] and Tourette syndrome.[4]
| |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C7H9F2NO2 |
| Molar mass | 177.151 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
CPP-115 is a GABA aminotransferase (GABA-AT) inactivator.[1]
History
CPP-115 was discovered in the research laboratory of Richard B. Silverman, for which he received the E. B. Hershberg Award for Important Discoveries in Medicinally Active Substances.[5] It was licensed to Catalyst Pharmaceuticals for development in 2009.[6][7]
CPP-115 has been granted orphan drug status for the treatment of infantile spasms by the FDA and for the treatment of West syndrome by the European Commission.[8]
As of 2022, CPP-115 is in Phase II clinical trials for Tourette syndrome.[4]